Regal Partners Ltd Raises Holdings in OR Royalties Inc. $OR

Regal Partners Ltd increased its stake in shares of OR Royalties Inc. (NYSE:OR) by 100.5% in the 1st quarter, HoldingsChannel reports. The firm owned 38,102 shares of the basic materials company’s stock after buying an additional 19,102 shares during the quarter. Regal Partners Ltd’s holdings in OR Royalties were worth $1,449,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. The Manufacturers Life Insurance Company grew its holdings in OR Royalties by 3.8% during the 1st quarter. The Manufacturers Life Insurance Company now owns 635,500 shares of the basic materials company’s stock valued at $24,176,000 after buying an additional 23,319 shares during the last quarter. SummitTX Capital L.P. purchased a new position in OR Royalties during the first quarter worth $6,810,000. Themes Management Co LLC acquired a new position in shares of OR Royalties in the first quarter worth $247,000. Healthcare of Ontario Pension Plan Trust Fund acquired a new position in shares of OR Royalties in the first quarter worth $1,912,000. Finally, Renaissance Technologies LLC lifted its position in shares of OR Royalties by 86.2% in the first quarter. Renaissance Technologies LLC now owns 783,302 shares of the basic materials company’s stock valued at $29,781,000 after acquiring an additional 362,700 shares in the last quarter. Hedge funds and other institutional investors own 68.52% of the company’s stock.

OR Royalties Stock Down 0.3%

Shares of OR Royalties stock opened at $29.44 on Wednesday. OR Royalties Inc. has a fifty-two week low of $27.40 and a fifty-two week high of $48.06. The firm has a market cap of $5.51 billion, a PE ratio of 21.97 and a beta of 0.74. The business’s fifty day moving average is $32.49 and its two-hundred day moving average is $37.74.

OR Royalties (NYSE:OR) last posted its quarterly earnings data on Wednesday, May 6th. The basic materials company reported $0.40 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.34 by $0.06. The business had revenue of $102.83 million for the quarter, compared to analysts’ expectations of $103.27 million. OR Royalties had a return on equity of 15.10% and a net margin of 78.09%. Equities research analysts anticipate that OR Royalties Inc. will post 1.27 EPS for the current year.

OR Royalties Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, July 15th. Investors of record on Tuesday, June 30th were given a dividend of $0.065 per share. This represents a $0.26 annualized dividend and a yield of 0.9%. This is a boost from OR Royalties’s previous quarterly dividend of $0.06. The ex-dividend date was Tuesday, June 30th. OR Royalties’s dividend payout ratio (DPR) is currently 18.66%.

Analyst Upgrades and Downgrades

A number of research firms recently commented on OR. Weiss Ratings lowered OR Royalties from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Friday. Royal Bank Of Canada cut their target price on shares of OR Royalties from $50.00 to $45.00 and set an “outperform” rating for the company in a research note on Thursday, July 9th. Wall Street Zen lowered shares of OR Royalties from a “buy” rating to a “hold” rating in a report on Saturday, June 6th. Zacks Research cut shares of OR Royalties from a “hold” rating to a “strong sell” rating in a research note on Monday, July 13th. Finally, Jefferies Financial Group lowered their price target on shares of OR Royalties from $40.00 to $34.00 and set a “hold” rating for the company in a report on Monday, July 6th. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $40.50.

OR Royalties Profile

OR Royalties PLC (NYSE: OR) is a closed-ended investment company that specializes in acquiring and managing royalty interests in life science and pharmaceutical products. The company provides capital to biotechnology, specialty pharmaceutical and medical device companies in exchange for a share of future sales revenues. By focusing on royalties secured against marketed products, OR Royalties aims to deliver income and growth potential while minimizing the development and commercialization risks typically associated with direct equity stakes.

The company’s core activities include sourcing royalty transactions, structuring bespoke financing solutions and actively monitoring a diversified portfolio of assets.